|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bulimia Nervosa | |||||
| Eating Disorders | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Bulimia | |||||
| 3 | More general conditions related to this trial | ||||
| Hyperphagia | |||||
| Mental Disorders | |||||
| Signs and Symptoms | |||||
| Signs and Symptoms, Digestive | |||||
| 4 | Interventions listed in this trial | ||||
| Erythromycin | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Erythromycin Estolate | |||||
| Erythromycin Ethylsuccinate | |||||
| Erythromycin stearate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Enzyme Inhibitors | |||||
| Gastrointestinal Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Synthesis Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||